Company overview
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. Its product candidate includes verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, as well as in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Daily valuation snapshot
These values are from the stored daily market snapshot dated 2026-10-08. They are not a live quote.
| Daily close (USD) | $4.55 |
| Market capitalization (USD) | $249,208,236.55 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.92 |
No matching rows. Clear the filter to see all records.
Continue the research
Read public ownership disclosures separately from company fundamentals. Test a strategy against dated historical observations before evaluating its assumptions; a past result is not a live trading outcome.